Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer to initiate pivotal study

Boehringer to initiate pivotal study

7th September 2007

Boehringer Ingelheim has announced that it intends to start phase III pivotal trials for new oncology compound BIBW 2992.

The announcement came at the World Conference on Lung Cancer (WCLC) and coincided with the presentation of key data for BIBW 2992 and its potential role in lung cancer treatment.

Lead study investigator Dr James Spicer acknowledged the importance of the ongoing pursuit for a “cancer cure”, but insisted that it was essential to develop more advanced treatment options which provided improved patient outcomes.

Dr Spicer, who is also a senior lecturer and consultant at King’s College School of Medicine at Guy’s Hospital in London, said: “Novel, irreversibly binding agents like BIBW 2992 provide us with a glimpse of the next chapter in the evolution of lung cancer care.”

Currently in phase II development, BIBW 2992 has shown particular effectiveness when used on lung cancer patients with specific genetic mutations, while also holding promise for activity against tumours resistant to first-generation inhibitors, as a result of its irreversible dual inhibition of EGFR and HER2.

Details of prospective phase III trials for BIBW 2992 are currently being finalised by both the Food and Drug Administration in the US and the European Agency for the Evaluation of Medicinal Products.

The 12th WCLC is currently being held in Seoul, South Korea and sees the world’s top lung cancer specialists present a series of studies on new developments in the treatment of lung cancer.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.